Business Wire

Chart Streams in cTrader by Spotware: Broadcast Your Technical Analysis 24/7

Share

cTrader Web presents Chart Streams, allowing users to broadcast their technical analysis 24/7 by sending a simple link to their audience. Users can watch a Chart Stream in guest mode even if they are not registered in cTrader yet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230305005002/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Chart Streams in cTrader (Photo: Spotware)

Use Chart Streams as an Educational Tool

For trading educators and strategy providers, this means the opportunity to grow their follower base by showcasing their skills. Also, their audience gets to benefit from a more detailed technical analysis education and the formation of stronger ties with their mentors. Watchers see the Chart Stream inside the live platform interface with total immersion into the trading process. They can also copy the chart with technical analysis from the Stream, open and edit it in a new window.

Start a Chart Stream

  1. Open the cTrader Web app
  2. Click the broadcast icon in a chart header
  3. Write a title and start your Stream
  4. Copy link and share with your audience

The Stream provider doesn’t need to be online all the time. The Stream will continue even if he closes the browser and switches off his laptop. So the Stream is available at any time for anyone who has the link. To end your Stream, click the “Stop” button or just close the chart window.

Spotware’s Head of Product, Alexander Strelnikov, says, “The Chart Streams feature is a major one for both professional educators and mentors, as well as their audiences. The ability to monitor a chart 24/7, seeing every update and indicator addition live, goes a long way towards improving one's own understanding of technical analysis, and helps create stronger trust bonds between mentors and followers. This way, it’s a win-win: professional traders and strategy providers grow their follower bases, while followers gain a new format of trading education. We are confident that the addition of this feature will prove to be a valuable part of the cTrader Web experience for all our users.”

Check out the Chart Stream from cTrader here .

About Spotware and cTrader

cTrader, a premium trading platform offered by leading brokers and trusted by millions of traders worldwide, is the flagship product of Spotware. cTrader is a one-of-a-kind platform that doesn’t engage in trader fraud and prides itself on 100% transparency while providing brokers with a complete solution that raises their brand value by putting them in a category of brokers that can be trusted while simultaneously catering to the needs of all their traders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Svetlana Krysanova
+357 25 344 901
skrysanova@spotware.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product8.6.2023 00:12:00 EEST | Press release

RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict

IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 23:18:00 EEST | Press release

IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating

Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 22:00:00 EEST | Press release

Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla

Brenus Pharma announces its international Scientific Committee7.6.2023 19:00:00 EEST | Press release

Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLI MD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL 2, Dijon. (FR) Head of the Board Pr Ahmad AWADA MD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active m

Lunaphore and CST Partnership Advances Spatial Biology Research with Over 1,700 IHC-Validated Antibodies for Use on COMET™7.6.2023 17:00:00 EEST | Press release

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced a partnership to enable the use of CST® antibodies on the Lunaphore COMET™ platform, a scalable hyperplex imaging solution for fully automated spatial biology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005502/en/ CST is a trusted provider of high-quality, rigorously validated antibodies for immunohistochemistry (IHC) that can detect key proteins in a variety of disease states. This partnership enables the use of over 1,700 IHC-validated antibodies from CST detected by fluorescent secondary antibodies for use on the COMET™, empowering researchers to develop antibody panels quickly and with confidence. With a comprehensive offering of primary rabbit and mous

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom